MO

Business Context and Reporting Period

Company: Altria Group, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Altria operates a leading portfolio of tobacco products for U.S. consumers age 21+, including smokeable products (cigarettes, cigars), oral tobacco products (moist smokeless tobacco, nicotine pouches), and e-vapor products. The company is executing a strategy to transition adult smokers to smoke-free alternatives ("Moving Beyond Smoking"). Key subsidiaries include Philip Morris USA, UST LLC, Helix Innovations, and NJOY. The company also holds significant equity investments in Anheuser-Busch InBev (ABI) and Cronos Group Inc.

Key Financial Metrics

Note: Adjusted metrics exclude special items such as asset impairments, litigation costs, and acquisition-related charges.

Material Changes vs. Prior Period

• Revenue Decline: Net revenues decreased 3.1% primarily due to lower shipment volumes in the smokeable products segment (cigarettes down 10.0%), partially offset by pricing actions.
• Significant Impairments: Reported net earnings were heavily impacted by non-cash impairments totaling $2.13 billion in the e-vapor segment (goodwill and definite-lived intangible assets) due to the ITC exclusion order on NJOY ACE and the proliferation of illicit e-vapor products. A $354 million impairment of the Skoal trademark occurred in 2024.
• Segment Performance:
  • Smokeable Products: Revenues declined 3.4%; Adjusted Operating Companies Income (OCI) increased 1.3% driven by pricing and lower settlement charges.
  • Oral Tobacco Products: Revenues increased 0.9%; Adjusted OCI increased 1.3% despite volume declines in moist smokeless tobacco (MST) offset by growth in nicotine pouches.
  • E-Vapor Products: Reported a loss of $2.30 billion in OCI due to impairments and litigation costs related to the NJOY acquisition.
• Share Repurchases: The company repurchased approximately 17.1 million shares in 2025 under a $2.0 billion program, reducing shares outstanding and supporting EPS.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• 2028 Goals: Altria targets mid-single digit adjusted diluted EPS CAGR through 2028, a debt-to-EBITDA ratio of approximately 2.0x, and maintaining a total adjusted OCI margin of at least 60%.
• Smoke-Free Portfolio: Management continues to reassess smoke-free goals due to market disruption from illicit e-vapor products. They expect effective enforcement against illicit products to occur more gradually than initially anticipated.
• Optimize & Accelerate Initiative: A multi-phase initiative launched in 2024 aims to deliver cumulative savings of at least $600 million by the end of 2029 through process modernization and centralization.
• Dividends: The quarterly dividend was increased to $1.06 per share in Q3 2025. The company targets mid-single digit annual dividend growth through 2028.

Key Risks and Contingencies

• Illicit Trade: The proliferation of illicit flavored disposable e-vapor products (estimated at 70% of the category) is driving cigarette volume declines and negatively impacting the e-vapor business outlook.
• Regulatory and Litigation:
  • ITC Orders: NJOY ACE is subject to exclusion and cease-and-desist orders prohibiting importation and sale in the U.S., pending appeal.
  • Patent Litigation: Ongoing patent infringement lawsuits involving NJOY Daily and JUUL products.
  • Health Care Litigation: Continued exposure to tobacco-related litigation, including Engle progeny cases and health care cost recovery actions.
• Consumer Behavior: Discretionary income pressures are driving consumers toward discount brands and cross-category movement to illicit products.

Investor Verification Checklist

• Impairment Assumptions: Verify the sensitivity of the e-vapor reporting unit's fair value to changes in discount rates and assumptions regarding the timing of enforcement against illicit e-vapor products.
• ITC Appeal Status: Monitor the progress of the appeal regarding the ITC exclusion order on NJOY ACE and potential outcomes for NJOY Daily patent litigation.
• Volume Trends: Track the rate of decline in domestic cigarette volumes versus the growth of illicit e-vapor products to assess the sustainability of the smokeable segment's pricing power.
• Debt Maturities: Review the schedule of long-term debt maturities, noting $1.57 billion due in 2026 and $1.22 billion in 2027.
• Regulatory Environment: Assess the impact of potential FDA actions on menthol cigarettes, flavored e-vapor products, and nicotine levels in combustible products.